Along with the increased prevalence of metabolic syndrome, such as obesity and hepatic steatosis, previous studies have exclusively focused on SREBP1-mediated de novo lipogenesis (Moslehi and Hamidi-Zad, 2018; Shimano and Sato, 2017). Here, SREBF1 is linked to fatty liver disease.